Source: Eur Respir J 2014; 43: 289-292



Rating:

Share or cite this content

Citations should be made in the following way:
Tiberi Simon, De Lorenzo Saverio, Centis Rosella, Viggiani Pietro, D’Ambrosio Lia, Migliori Giovanni Battista. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292

Member's Comments

No comment yet.

Related content which might interest you: ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use Source: Eur Respir J 2014; 44: 811-815 Year: 2014 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Compassionate use of bedaquiline in a cohort of Indian drug resistant tuberculosis(DR-TB) patients Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Exercise: management of MDR/XDR-TB cases: discussion of clinical cases provided by participants Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Managing adult and children XDR-TB cases with limited clinical options Source: International Congress 2018 – CC4 Tuberculosis Year: 2018 Managing difficult TB cases: experiences from the ERS/WHO TB Consilium and other country-specific Consilia Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Cross-border management of tuberculosis cases through an updated ERS/WHO TB consilium Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 The experience of complex treatment of XDR-TB patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019